Vaxin Inc.: Difference between revisions
(New page: '''Vaxin Inc.'' is a vaccine development company founded in 1997 by De-chu Tang to commercialize his research at UAB. It is currently working on vaccines for influenza and anth...) |
No edit summary |
||
| Line 1: | Line 1: | ||
'''Vaxin Inc.'' is a vaccine development company founded in [[1997]] by [[De-chu Tang]] to commercialize his research at [[UAB]]. It is currently working on vaccines for influenza and anthrax, largely with funding from the U. S. Department of Health and Human Services. Research is also being conducted toward vaccine programs for avian influenza, tetanus and Alzheimer's. | '''Vaxin Inc.''' is a vaccine development company founded in [[1997]] by [[De-chu Tang]] to commercialize his research at [[UAB]]. It is currently working on vaccines for influenza and anthrax, largely with funding from the U. S. Department of Health and Human Services. Research is also being conducted toward vaccine programs for avian influenza, tetanus and Alzheimer's. | ||
Vaxin moved its laboratories into [[Birmingham]]'s [[Innovation Depot]] in [[2007]]. [[Bill Enright]] became CEO in [[2008]]. He and other executives worked from offices in Gaithersburg, Maryland. In Spring [[2012]] the company, with 8 full-time employees, consolidated its operations in Maryland. | Vaxin moved its laboratories into [[Birmingham]]'s [[Innovation Depot]] in [[2007]]. [[Bill Enright]] became CEO in [[2008]]. He and other executives worked from offices in Gaithersburg, Maryland. In Spring [[2012]] the company, with 8 full-time employees, consolidated its operations in Maryland. | ||
Revision as of 07:25, 27 July 2012
Vaxin Inc. is a vaccine development company founded in 1997 by De-chu Tang to commercialize his research at UAB. It is currently working on vaccines for influenza and anthrax, largely with funding from the U. S. Department of Health and Human Services. Research is also being conducted toward vaccine programs for avian influenza, tetanus and Alzheimer's.
Vaxin moved its laboratories into Birmingham's Innovation Depot in 2007. Bill Enright became CEO in 2008. He and other executives worked from offices in Gaithersburg, Maryland. In Spring 2012 the company, with 8 full-time employees, consolidated its operations in Maryland.
Vaxin, partly owned by the UAB Research Foundation, is partnering with fellow Innovation Depot tenant Soluble Therapeutics in seeking grants related to studying vaccine stabliity.
References
- Swant, Martin (July 27, 2012) "Vaxin moves from Birmingham to Maryland." The Birmingham News
External links
- Vaxin Inc. website